BIO-Europe Spring® 2017: Digimed and diagnostics: Market access and new collaborations

April 6, 2017
The effect of digital medicine on diagnostics is having and will continue to have a revolutionary effect on the interactions between patients and their healthcare providers and between the healthcare system and its service and support providers. While these changes herald more streamlined and to some extent personalized treatments for patients, the dynamic of these relationships will also have profound effects on treatment decisions. We examine the factors digital medicine companies face in gaining market access.
Previous Video
BIO-Europe Spring® 2017: Seventure Partners predicts bright future for microbiome opportunities
BIO-Europe Spring® 2017: Seventure Partners predicts bright future for microbiome opportunities

Seventure Partners’ Eric de la Fortelle explains to Informa Pharma Intelligence’s Mike Ward how the venture...

Next Video
BIO-Europe Spring® 2017: Stirring the entrepreneurial pot in Europe
BIO-Europe Spring® 2017: Stirring the entrepreneurial pot in Europe

Europe is home to many of the biggest pharma companies and the best academic biomedical researchers. But th...